Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
08/09/2026 11:16
BRIEF-Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity Sept 8 (Reuters) - Ascletis Pharma Inc. 1672.HK:
INITIATES U.S. PHASE I STUDY FOR ASC36 ORAL TABLETS FOR OBESITY
RECEIVES IND CLEARANCE FROM U.S. FDA FOR ASC36 ORAL TABLETS
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management